insights_auto
Why is NVV1 up 5.23%?
Dive Deeperchevron_right
NVV1:FRA
Novavax Inc
€10.06
arrow_upward
+5.23%(+0.50) 1D
Oct 21, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVV1...
Open
€10.20
High
€10.20
Low
€9.84
Mkt. cap
1.82B
Avg. vol.
3.03K
Volume
0.00
52-wk high
€11.84
52-wk low
€5.41
No. of employees
749
Open
€10.20
High
€10.20
Low
€9.84
Mkt. cap
1.82B
Avg. vol.
3.03K
Volume
0.00
52-wk high
€11.84
52-wk low
€5.41
No. of employees
749
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
3 Reasons NVAX is Risky and 1 Stock to Buy Instead
Yahoo Finance
·
2 days ago
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors
Barron's
·
5 days ago
Why Moderna Stock, Novavax, and Revolution Medicines Are Slumping Today
24/7 Wall St.
·
5 days ago
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com